Rezolute to present Phase 3 sunRIZE study results at PES meeting

April 21, 2026 7:01 AM

Rezolute Inc. (NASDAQ: RZLT) announced that results from its Phase 3 sunRIZE study of ersodetug in congenital hyperinsulinism will be ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found